Plain-English translation of NCT07593482 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether bendamustine is a safer alternative to the standard two-drug combination ( and ) given before CAR-T cell therapy. Both groups receive chemotherapy before their CAR-T cells are infused, but this study compares which preparation method may cause fewer serious side effects while still helping the CAR-T cells work effectively.
CAR-T cell therapy is an effective treatment for certain blood cancers, but the standard pre-treatment chemotherapy can cause serious side effects like infections and dangerous immune reactions that sometimes lead to hospitalization or death. This trial is exploring whether the new treatment might provide similar benefits with fewer of these complications.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either bendamustine or the standard two-drug combination as your pre-treatment before CAR-T cell therapy. The study involves receiving your assigned pre-treatment chemotherapy, followed by the CAR-T cell infusion and monitoring for side effects. You will be part of a research group of 92 patients total, helping doctors determine which preparation method is safer and most effective.
AI-generated summary from trial data · Oct 22, 2026 · Not medical advice
Switzerland